Skip to main content

Table 2 Perioperative variables of the matched groups

From: The long-term efficacy of one-shot neoadjuvant intra-arterial chemotherapy combined with radical cystectomy versus radical cystectomy alone for bladder cancer: a propensity-score matching study

 Intra-arterialNo Intra-arterialp value
Patients (n)2678 
Type of urinary diversion, n (%)0.840
Cutaneous ureterostomy2(7.7%)5(6.4%)
Ileal conduit9(34.6%)32(41.0%)
Orthotopic neobladder15(57.7%)41(52.6%)
Operating time, min, mean (IQR)369.0(300.0–420.0)382.9(306.0–420.0)0.574
Estimated blood loss, ml, mean (IQR)411.5(187.5–525.0)348.1(200.0–400.0)0.456
Removed Jackson-Pratt drain, day, mean (IQR)12.6(9.0–14.3)14.7(8.0–19.0)0.591
Passing flatus, day, mean (IQR)4.9(3.0–6.0)4.0(3.0–5.0)0.189
Adjuvant chemotherapy, n (%)4(15.4%)12(15.4%)1.000
Pre-op laboratory studies
HGB (g/L), median (IQR)134.0(122.3–142.3)132.5(119.8–146.3)0.943
HCT (%), median (IQR)38.6(36.9–41.5)39.8(36.1–42.4)0.615
WBC, median (IQR)6.4(5.0–7.6)6.5(5.3–7.8)0.286
Platelets, median (IQR)218.5(193.0–262.5)216.5(187.3–258.5)0.768
BUN(mmol/L), median (IQR)5.7(4.7–7.0)6.1(4.6–8.0)0.119
Creatinine(μmol/L), median (IQR)84.2(70.3–113.5)82.2(70.1–99.9)0.702
Albumin (g/L), median (IQR)35.1(32.8–39.0)36.0(33.0–39.9)0.931
Overall complications, n (%), Clavien grade24(92.3%)75(96.2%)0.791
Perioperative complications (<  30 d), n (%),0.930
02(7.7%)3(3.8%) 
10(0.0%)2(2.6%) 
221(80.8%)66(84.6%) 
33(11.5%)5(6.4%) 
40(0.0%)0(0.0%) 
Short-term complications (<  90 d), n (%)0.516
024(92.3%)68(87.2%)
10(0.0%)4(5.1%)
21(3.8%)3(3.8%)
31(3.8%)3(3.8%)
40(0.0%)0(0.0%)
Long-term complications (>90 d), n (%)0.616
024(92.3%)74(94.9%)
10(0.0%)0(0.0%)
20(0.0%)0(0.0%)
31(3.8%)3(3.8%)
41(3.8%)1(1.3%)
Surgery intensive care unit stay, n (%)0(0.0%)8(10.3%)0.196
  1. IQR = interquartile range; HGB = hemoglobin; HCT = hematocrit; WBC = white blood cell; BUN = blood urea nitrogen